Table 5.

Characteristics of discussed studies of rituximab in idiopathic MPGN

Study	Study design	Population	Rituximab protocol	Selected outcomes	Results
Kong et al35	Retrospective case review	24 patients with primary glomerular disease	One patient received a single infusion of rituximab 375 mg/m2	CR: UPCR <30 mg/mmol and serum albumin ≥35 g/L	One patient achieved CR after 19 months
		Included two patients with idiopathic MPGN	The other received two rituximab infusions at 375 mg/m2	PR: UPCR between 30 and 300 mg/mmol and serum albumin ≥30 g/L	One patient achieved PR after 29 months
				Adverse events	No serious adverse events during follow-up
Sugiura et al32	Prospective, single-arm trial	24 patients with primary glomerular disease	Single dose of 375 mg/m2	Proteinuria at 6 months	In one patient with MPGN, proteinuria decreased from 9.8 g/day at baseline to 1.8 g/day at 6 months
		Included one patient with idiopathic MPGN
Dillon et al36	Prospective, single-arm trial	Six patients with MPGN (four idiopathic, two with cryoglobulinemia)	1 g on days 1 and 15	CR: proteinuria ≤0.3 g/day without doubling of serum creatinine	The two patients with MPGN and cryoglobulinemia achieved CR at 12 months
				PR: proteinuria between 0.3 and 3.5 g/day without doubling of serum creatinine	The four patients with idiopathic MPGN achieved PR at 12 months
				Adverse events	No adverse events during follow-up

Abbreviations: CR, complete remission; MPGN, membranoproliferative glomerulonephritis; PR, partial remission; UPCR, urine protein over creatinine ratio.